Unlocking Rapid, High‑Fidelity mRNA Production with Gibson Assembly® Executive summary
04 Aug 2025
The race to develop mRNA vaccines, therapeutics, and cell‑engineering reagents has exposed a bottleneck that traditional restriction‑enzyme or Type IIS cloning cannot escape: every change to a UTR, codon‑optimized open reading frame (ORF), or regulatory element demands a new set of enzymes, scar‑removal steps, and days of sub‑cloning.